Asia PacificENPublic regulatory overview
Vietnam
Country Overview Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing Healthcare system: Universal health insurance (BHYT — Bảo hiểm y...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Vietnam
- Product line: Medical devices
- Regulator / source: Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
- Local requirement: Vietnam medical-device entry should be separated into Ministry of Health medical-device authorities and online classification / declaration systems regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Country Overview
- Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing
- Healthcare system: Universal health insurance (BHYT — Bảo hiểm y tế) covers approximately 93% of the population, but reimbursement levels are limited. Public hospitals dominate (approximately 85% of healthcare resources); private hospitals are growing rapidly. Healthcare infrastructure is concentrated in Hanoi (north) and Ho Chi Minh City (south).
- Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
- Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.
Market-Entry Logic
Vietnam medical-device entry should be separated into Ministry of Health medical-device authorities and online classification / declaration systems regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
| Entry layer | Key question | Practical view |
|---|---|---|
| Regulatory route | Which product category, risk class, application type, reliance route, or special pathway applies? | Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations |
| Local execution | Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? | Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product |
| Evidence and economics | What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? | Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption |
| Channel access | Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? | Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion |
Main Players and Channel Map
| Type | Representative players | Market meaning |
|---|---|---|
| Regulator / review | Ministry of Health medical-device authorities and online classification / declaration systems | Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations |
| Payment / procurement | Vietnam Social Security, public hospital tenders and growing private hospital chains | Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability |
| Companies / channels | local importers, hospital distributors, FV Hospital, Vinmec, Hoan My, public hospitals and multinational medtech suppliers | Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks |
| End users / buyers | Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors | Determine adoption, tender volume, reference cases, service expectations, and receivables risk |
Development Trends
- Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
- Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
- Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
- Pricing pressure is structural: regulatory transition, tender transparency, local importer control, hospital autonomy, private hospital growth and ASEAN supply-chain positioning are reshaping launch sequencing and product economics.
- Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.
Regulatory Authority
- Primary authority: DAV (Drug Administration of Vietnam — Cục Quản lý Dược), under the Ministry of Health (MOH — Bộ Y tế). Note: Following the 2023 institutional reform, medical device regulatory functions were consolidated under DAV (previously under the Medical Equipment and Construction Division — DTBYT). Verify the current institutional name when submitting.
- Official portal: https://dav.gov.vn; Medical device registration system: https://dichvucong.moh.gov.vn (MOH Public Services Portal)
- Key regulations:
- Decree No. 98/2021/ND-CP on Medical Device Management (effective November 2021; supersedes Decree 36/2016)
- Circular No. 05/2022/TT-BYT (implementing regulations for Decree 98/2021)
- Circular on Medical Device Classification Guidelines
- Historical reference: Decree 36/2016 (superseded), Circular 30/2015 (updated)
Device Classification System
| Local Class | Risk Level | Approximate EU/FDA Equivalent | Notes |
|---|---|---|---|
| Type A (Loại A) | Lowest risk | EU Class I / FDA Class I | Declaration/notification (khai báo); relatively simple procedure |
| Type B (Loại B) | Low-Moderate risk | EU Class IIa / FDA Class II | Full marketing authorization required (đăng ký lưu hành); faster review |
| Type C (Loại C) | Moderate-High risk | EU Class IIb / FDA Class III | Marketing authorization required; rigorous review with technical verification |
| Type D (Loại D) | Highest risk | EU Class III / FDA PMA | Most stringent review; complete technical documentation + local technical testing required |
Note: Classification is based on the annexes of Decree 98/2021. Classification requests can be submitted to DAV (approximately 4–8 weeks for a determination). IVD products follow a separate classification scheme (based on the WHO IVD classification framework).
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.